Gland Pharma enters into put option agreement to acquire 100% stake in Cenexi Group

30 Nov 2022 Evaluate

Gland Pharma through its wholly owned subsidiary -- Gland Pharma International PTE, Singapore has entered into a Put Option agreement to acquire 100% of Cenexi Group for an equity value not exceeding Euro 120 million (Enterprise Value of Euro 230 million).

Founded in 2004, Cenexi, along with its Subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill-finished drug, including capabilities on oncology and complex products. It has presence across four manufacturing sites in Europe which include three sites in France and one site in Belgium.

Gland Pharma has a strategic focus on expanding its CDMO offerings in the European market and build a manufacturing presence in the market. The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones. Gland Pharma’s ability to support future investments in expanding manufacturing footprint will help build Cenexi as a major CDMO player in the European market. Gland and Cenexi can leverage their long- standing customer relationships to generate synergistic benefit for both entities along with helping Gland enter the branded CDMO space.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1686.00 -64.55 (-3.69%)
08-Dec-2025 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 924.35
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×